Anti-GD2 immunotherapy for neuroblastoma.

about

Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy

P2860

Q56892924-5BBDC4EA-524D-4B17-90DE-94D35D5A0244

P2860

Anti-GD2 immunotherapy for neuroblastoma.

Item

http://www.wikidata.org/entity/Q47554435

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Anti-GD2 immunotherapy for neuroblastoma.

@en

Anti-GD2 immunotherapy for neuroblastoma.

@nl

type

Item

label

Anti-GD2 immunotherapy for neuroblastoma.

@en

Anti-GD2 immunotherapy for neuroblastoma.

@nl

prefLabel

Anti-GD2 immunotherapy for neuroblastoma.

@en

Anti-GD2 immunotherapy for neuroblastoma.

@nl

P1476

Anti-GD2 immunotherapy for neuroblastoma

@en

P2093

Sameer Sait

http://www.w3.org/2001/XMLSchema#string

P2860

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study

Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles

In silico Driven Redesign of a Clinically Relevant Antibody for the Treatment of GD2 Positive Tumors

Genomic organization and chromosomal assignment of the human beta1, 4-N-acetylgalactosaminyltransferase gene. Identification of multiple transcription units

SDR grafting--a new approach to antibody humanization

Signatures of mutational processes in human cancer

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group

Anti-GD2 antibody 3F8 and barley-derived (1 → 3),(1 → 4)-β-D-glucan: A Phase I study in patients with chemoresistant neuroblastoma

P304

889-904

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14737140.2017.1364995

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Shakeel Modak

P577

2017-08-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28780888

http://www.w3.org/2001/XMLSchema#string

P921

immunotherapy

P932

6082365

http://www.w3.org/2001/XMLSchema#string

Anti-GD2 immunotherapy for neuroblastoma.

about

P2860

P2860

Anti-GD2 immunotherapy for neuroblastoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932